1	6	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Challenges	_	_	NNS	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	MSC	_	_	NNP	_	_	_	_	_
4	Translation	_	_	NNP	_	_	_	_	_
5	into	_	_	IN	_	_	_	_	_
6	Clinical	_	_	JJ	_	_	_	_	_
7	Practice	_	_	NN	_	_	_	_	_
8	:	_	_	:	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	Bone	_	_	NNP	_	_	_	_	_
3	Disease	_	_	NNP	_	_	_	_	_
4	Framework	_	_	NN	_	_	_	_	_


1	Other	_	_	JJ	_	_	_	_	_
2	interesting	_	_	JJ	_	_	_	_	_
3	aspects	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	new	_	_	JJ	_	_	_	_	_
6	perspectives	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	field	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	tissue	_	_	NN	_	_	_	_	_
12	regeneration	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	applicative	_	_	JJ	_	_	_	_	_
15	use	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	MSC	_	_	NNP	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	strictly	_	_	RB	_	_	_	_	_
20	related	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	their	_	_	PRP$	_	_	_	_	_
23	potential	_	_	NN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	tackle	_	_	VB	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	increase	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	bone	_	_	NN	_	_	_	_	_
30	diseases	_	_	NNS	_	_	_	_	_
31	related	_	_	VBN	_	_	_	_	_
32	with	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	extended	_	_	VBN	_	_	_	_	_
35	life	_	_	NN	_	_	_	_	_
36	expectancy	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	many	_	_	JJ	_	_	_	_	_
5	countries	_	_	NNS	_	_	_	_	_
6	bone	_	_	NN	_	_	_	_	_
7	diseases	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	becoming	_	_	VBG	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	relevant	_	_	JJ	_	_	_	_	_
12	cause	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	disability	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	even	_	_	RB	_	_	_	_	_
17	if	_	_	IN	_	_	_	_	_
18	they	_	_	PRP	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	acute	_	_	JJ	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	such	_	_	JJ	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	fractures	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	or	_	_	CC	_	_	_	_	_
27	chronic	_	_	JJ	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	such	_	_	JJ	_	_	_	_	_
30	as	_	_	IN	_	_	_	_	_
31	osteoporosis	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	tumours	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	any	_	_	DT	_	_	_	_	_
3	case	_	_	NN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	pathologies	_	_	NNS	_	_	_	_	_
6	require	_	_	VBP	_	_	_	_	_
7	treatments	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	enhance	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	healing	_	_	VBG	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	regenerative	_	_	JJ	_	_	_	_	_
14	capacity	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	bone	_	_	NN	_	_	_	_	_
17	tissue	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	common	_	_	JJ	_	_	_	_	_
3	therapeutic	_	_	JJ	_	_	_	_	_
4	strategies	_	_	NNS	_	_	_	_	_
5	based	_	_	VBN	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	bone	_	_	NN	_	_	_	_	_
8	grafting	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	autografts	_	_	NNS	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	allografts	_	_	NNS	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	show	_	_	VBP	_	_	_	_	_
15	some	_	_	DT	_	_	_	_	_
16	disadvantages	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Autografts	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	limited	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	bone	_	_	NN	_	_	_	_	_
7	volume	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	harvested	_	_	VBN	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	iliac	_	_	JJ	_	_	_	_	_
15	crest	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	present	_	_	VBP	_	_	_	_	_
18	surgical	_	_	JJ	_	_	_	_	_
19	risks	_	_	NNS	_	_	_	_	_
20	such	_	_	JJ	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	bleeding	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	inflammation	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	infection	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	chronic	_	_	JJ	_	_	_	_	_
29	pain	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	damage	_	_	NN	_	_	_	_	_
32	at	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	donor	_	_	NN	_	_	_	_	_
35	site	_	_	NN	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	morbidity	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Allografts	_	_	NNS	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	limitations	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	such	_	_	JJ	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	lack	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	donors	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	high	_	_	JJ	_	_	_	_	_
15	costs	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	need	_	_	NN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	sterilization	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	risk	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	infectious	_	_	JJ	_	_	_	_	_
26	agent	_	_	NN	_	_	_	_	_
27	transmission	_	_	NN	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	immune	_	_	JJ	_	_	_	_	_
30	mediated	_	_	VBN	_	_	_	_	_
31	tissue	_	_	NN	_	_	_	_	_
32	rejection	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	limitations	_	_	NNS	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	disadvantages	_	_	NNS	_	_	_	_	_
5	associated	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	auto-	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	allograft	_	_	NN	_	_	_	_	_
10	approaches	_	_	NNS	_	_	_	_	_
11	indicate	_	_	VBP	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	clinical	_	_	JJ	_	_	_	_	_
14	need	_	_	NN	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	alternative	_	_	JJ	_	_	_	_	_
17	therapeutic	_	_	JJ	_	_	_	_	_
18	strategies	_	_	NNS	_	_	_	_	_
19	aimed	_	_	VBN	_	_	_	_	_
20	at	_	_	IN	_	_	_	_	_
21	bone	_	_	NN	_	_	_	_	_
22	healing	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	regeneration	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	new	_	_	JJ	_	_	_	_	_
4	biomaterials	_	_	NNS	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	scaffolds	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	association	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	MSC	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	growth	_	_	NN	_	_	_	_	_
14	factors	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	having	_	_	VBG	_	_	_	_	_
17	requirements	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	biocompatibility	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	osteoinductive	_	_	JJ	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	osteoconductive	_	_	JJ	_	_	_	_	_
24	properties	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	are	_	_	VBP	_	_	_	_	_
27	investigated	_	_	VBN	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	improve	_	_	VB	_	_	_	_	_
30	bone	_	_	NN	_	_	_	_	_
31	repair	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	use	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	MSC	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	attractive	_	_	JJ	_	_	_	_	_
7	since	_	_	IN	_	_	_	_	_
8	they	_	_	PRP	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	harvested	_	_	VBN	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	host	_	_	NN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	minimal	_	_	JJ	_	_	_	_	_
17	morbidity	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	they	_	_	PRP	_	_	_	_	_
20	can	_	_	MD	_	_	_	_	_
21	be	_	_	VB	_	_	_	_	_
22	modified	_	_	VBN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	secrete	_	_	VB	_	_	_	_	_
25	osteoinductive	_	_	JJ	_	_	_	_	_
26	factors	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	implanted	_	_	VBN	_	_	_	_	_
29	on	_	_	IN	_	_	_	_	_
30	an	_	_	DT	_	_	_	_	_
31	osteoconductive	_	_	JJ	_	_	_	_	_
32	scaffold	_	_	NN	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	to	_	_	TO	_	_	_	_	_
35	obtain	_	_	VB	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	three	_	_	CD	_	_	_	_	_
38	key	_	_	JJ	_	_	_	_	_
39	components	_	_	NNS	_	_	_	_	_
40	leading	_	_	VBG	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	osteogenesis	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	hMSC	_	_	NNP	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	found	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	adult	_	_	JJ	_	_	_	_	_
8	tissues	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	including	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	synovial	_	_	JJ	_	_	_	_	_
13	membrane	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	adipose	_	_	NN	_	_	_	_	_
17	tissue	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	dental	_	_	JJ	_	_	_	_	_
21	pulp	_	_	NN	_	_	_	_	_
22	tissue	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	perinatal	_	_	JJ	_	_	_	_	_
27	tissues	_	_	NNS	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	umbilical	_	_	JJ	_	_	_	_	_
30	cord	_	_	NN	_	_	_	_	_
31	blood	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	umbilical	_	_	JJ	_	_	_	_	_
34	cord	_	_	NN	_	_	_	_	_
35	tissue	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	All	_	_	PDT	_	_	_	_	_
2	these	_	_	DT	_	_	_	_	_
3	cells	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	suited	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	therapeutic	_	_	JJ	_	_	_	_	_
8	applications	_	_	NNS	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	bone	_	_	NN	_	_	_	_	_
11	regeneration	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	means	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	two	_	_	CD	_	_	_	_	_
17	different	_	_	JJ	_	_	_	_	_
18	ways	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	autologous	_	_	JJ	_	_	_	_	_
21	cells	_	_	NNS	_	_	_	_	_
22	transplantation	_	_	NN	_	_	_	_	_
23	:	_	_	:	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	1	_	_	CD	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	cell	_	_	NN	_	_	_	_	_
28	therapies	_	_	NNS	_	_	_	_	_
29	without	_	_	IN	_	_	_	_	_
30	expansion	_	_	NN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	culture	_	_	NN	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	one-step	_	_	JJ	_	_	_	_	_
35	procedure	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	(	_	_	-LRB-	_	_	_	_	_
39	2	_	_	CD	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	cell	_	_	NN	_	_	_	_	_
42	therapies	_	_	NNS	_	_	_	_	_
43	with	_	_	IN	_	_	_	_	_
44	ex	_	_	NN	_	_	_	_	_
45	vivo	_	_	NN	_	_	_	_	_
46	expansion	_	_	NN	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	first	_	_	JJ	_	_	_	_	_
4	case	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	harvested	_	_	VBN	_	_	_	_	_
9	during	_	_	IN	_	_	_	_	_
10	surgery	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2010	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	Jagër	_	_	NNP	_	_	_	_	_
5	et	_	_	FW	_	_	_	_	_
6	al.	_	_	FW	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	successfully	_	_	RB	_	_	_	_	_
9	treated	_	_	VBN	_	_	_	_	_
10	more	_	_	JJR	_	_	_	_	_
11	than	_	_	IN	_	_	_	_	_
12	100	_	_	CD	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	local	_	_	JJ	_	_	_	_	_
16	bone	_	_	NN	_	_	_	_	_
17	healing	_	_	NN	_	_	_	_	_
18	disorders	_	_	NNS	_	_	_	_	_
19	using	_	_	VBG	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	biomaterial	_	_	JJ	_	_	_	_	_
22	composite	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	association	_	_	NN	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	BM	_	_	NNP	_	_	_	_	_
27	aspiration	_	_	NN	_	_	_	_	_
28	concentrate	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	observed	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	use	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	BM	_	_	NNP	_	_	_	_	_
8	concentrate	_	_	NN	_	_	_	_	_
9	reduced	_	_	VBD	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	harvest	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	autogenous	_	_	JJ	_	_	_	_	_
14	bone	_	_	NN	_	_	_	_	_
15	by	_	_	IN	_	_	_	_	_
16	50	_	_	CD	_	_	_	_	_
17	%	_	_	NN	_	_	_	_	_
18	without	_	_	IN	_	_	_	_	_
19	negative	_	_	JJ	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	on	_	_	IN	_	_	_	_	_
22	bone	_	_	NN	_	_	_	_	_
23	healing	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	second	_	_	JJ	_	_	_	_	_
3	clinical	_	_	JJ	_	_	_	_	_
4	application	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	MSC	_	_	NNP	_	_	_	_	_
7	includes	_	_	VBZ	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	autologous	_	_	JJ	_	_	_	_	_
10	cell	_	_	NN	_	_	_	_	_
11	transplantation	_	_	NN	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	ex-vivo	_	_	NN	_	_	_	_	_
14	expansion	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	2007	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	Nöth	_	_	NNP	_	_	_	_	_
5	et	_	_	FW	_	_	_	_	_
6	al.	_	_	FW	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	used	_	_	VBD	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	cell	_	_	NN	_	_	_	_	_
11	population	_	_	NN	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	BM	_	_	NNP	_	_	_	_	_
14	aspirate	_	_	NN	_	_	_	_	_
15	cultured	_	_	VBN	_	_	_	_	_
16	over	_	_	IN	_	_	_	_	_
17	12	_	_	CD	_	_	_	_	_
18	days	_	_	NNS	_	_	_	_	_
19	under	_	_	IN	_	_	_	_	_
20	GMP	_	_	NN	_	_	_	_	_
21	conditions	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	transplanted	_	_	VBD	_	_	_	_	_
24	them	_	_	PRP	_	_	_	_	_
25	autologously	_	_	RB	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	tricalcium	_	_	NN	_	_	_	_	_
29	phosphate	_	_	NN	_	_	_	_	_
30	biomaterial	_	_	NN	_	_	_	_	_
31	for	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	treatment	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	femoral	_	_	JJ	_	_	_	_	_
36	head	_	_	NN	_	_	_	_	_
37	necrosis	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	main	_	_	JJ	_	_	_	_	_
3	limitations	_	_	NNS	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	clinical	_	_	JJ	_	_	_	_	_
6	application	_	_	NN	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	sterility	_	_	NN	_	_	_	_	_
10	technique	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	long	_	_	JJ	_	_	_	_	_
13	culture	_	_	NN	_	_	_	_	_
14	time	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	high	_	_	JJ	_	_	_	_	_
17	cost	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	mixture	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	human	_	_	JJ	_	_	_	_	_
24	cell	_	_	NN	_	_	_	_	_
25	culture	_	_	NN	_	_	_	_	_
26	medium	_	_	NN	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	fetal	_	_	JJ	_	_	_	_	_
29	bovine	_	_	NN	_	_	_	_	_
30	serum	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	recently	_	_	RB	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	orthopedic	_	_	JJ	_	_	_	_	_
6	researchers	_	_	NNS	_	_	_	_	_
7	focused	_	_	VBD	_	_	_	_	_
8	their	_	_	PRP$	_	_	_	_	_
9	attention	_	_	NN	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	clinical	_	_	JJ	_	_	_	_	_
13	use	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	BM	_	_	NNP	_	_	_	_	_
16	aspirate	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	BMA	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	BM	_	_	NN	_	_	_	_	_
22	concentrate	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	BMC	_	_	NNP	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	musculoskeletal	_	_	JJ	_	_	_	_	_
28	regeneration	_	_	NN	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	“	_	_	``	_	_	_	_	_
32	one-step	_	_	JJ	_	_	_	_	_
33	”	_	_	''	_	_	_	_	_
34	procedure	_	_	NN	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	avoiding	_	_	VBG	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	need	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	additional	_	_	JJ	_	_	_	_	_
41	laboratory	_	_	NN	_	_	_	_	_
42	stages	_	_	NNS	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	GMP	_	_	NN	_	_	_	_	_
45	facility	_	_	NN	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	thus	_	_	RB	_	_	_	_	_
48	reducing	_	_	VBG	_	_	_	_	_
49	costs	_	_	NNS	_	_	_	_	_
50	and	_	_	CC	_	_	_	_	_
51	risks	_	_	NNS	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	Bone	_	_	NN	_	_	_	_	_
2	marrow	_	_	NN	_	_	_	_	_
3	contains	_	_	VBZ	_	_	_	_	_
4	MSC	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	hematopoietic	_	_	JJ	_	_	_	_	_
7	stem	_	_	NN	_	_	_	_	_
8	cells	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	endothelial	_	_	JJ	_	_	_	_	_
11	progenitor	_	_	NN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	other	_	_	JJ	_	_	_	_	_
15	progenitor	_	_	NN	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	growth	_	_	NN	_	_	_	_	_
19	factors	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	including	_	_	VBG	_	_	_	_	_
22	bone	_	_	NN	_	_	_	_	_
23	morphogenetic	_	_	JJ	_	_	_	_	_
24	proteins	_	_	NNS	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	BMP	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	platelet-derived	_	_	JJ	_	_	_	_	_
30	growth	_	_	NN	_	_	_	_	_
31	factor	_	_	NN	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	PDGF	_	_	NN	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	transforming	_	_	VBG	_	_	_	_	_
37	growth	_	_	NN	_	_	_	_	_
38	factor-β	_	_	NN	_	_	_	_	_
39	(	_	_	-LRB-	_	_	_	_	_
40	TGF-β	_	_	NN	_	_	_	_	_
41	)	_	_	-RRB-	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	vascular	_	_	JJ	_	_	_	_	_
44	endothelial	_	_	JJ	_	_	_	_	_
45	growth	_	_	NN	_	_	_	_	_
46	factor	_	_	NN	_	_	_	_	_
47	(	_	_	-LRB-	_	_	_	_	_
48	VEGF	_	_	NN	_	_	_	_	_
49	)	_	_	-RRB-	_	_	_	_	_
50	,	_	_	,	_	_	_	_	_
51	interleukin-8	_	_	NN	_	_	_	_	_
52	(	_	_	-LRB-	_	_	_	_	_
53	IL-8	_	_	NN	_	_	_	_	_
54	)	_	_	-RRB-	_	_	_	_	_
55	,	_	_	,	_	_	_	_	_
56	and	_	_	CC	_	_	_	_	_
57	IL-1	_	_	NN	_	_	_	_	_
58	receptor	_	_	NN	_	_	_	_	_
59	antagonist	_	_	NN	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	identified	_	_	VBN	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	excellent	_	_	JJ	_	_	_	_	_
8	source	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	growth	_	_	NN	_	_	_	_	_
13	factors	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	it	_	_	PRP	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	used	_	_	VBN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	success	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	bone	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	cartilage	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	soft	_	_	JJ	_	_	_	_	_
27	tissue	_	_	NN	_	_	_	_	_
28	healing	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	focused	_	_	VBD	_	_	_	_	_
3	our	_	_	PRP$	_	_	_	_	_
4	attention	_	_	NN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	use	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	BM-derived	_	_	JJ	_	_	_	_	_
10	MSC	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	spinal	_	_	JJ	_	_	_	_	_
13	fusion	_	_	NN	_	_	_	_	_
14	surgical	_	_	JJ	_	_	_	_	_
15	procedures	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	most	_	_	RBS	_	_	_	_	_
21	definitive	_	_	JJ	_	_	_	_	_
22	treatment	_	_	NN	_	_	_	_	_
23	performed	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	restore	_	_	VB	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	structural	_	_	JJ	_	_	_	_	_
28	stability	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	spinal	_	_	JJ	_	_	_	_	_
32	column	_	_	NN	_	_	_	_	_
33	in	_	_	IN	_	_	_	_	_
34	degenerative	_	_	JJ	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	oncological	_	_	JJ	_	_	_	_	_
37	spine	_	_	NN	_	_	_	_	_
38	diseases	_	_	NNS	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Currently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	gold	_	_	NN	_	_	_	_	_
5	standard	_	_	NN	_	_	_	_	_
6	stimulus	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	achieve	_	_	VB	_	_	_	_	_
9	spinal	_	_	JJ	_	_	_	_	_
10	fusion	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	autologous	_	_	JJ	_	_	_	_	_
13	bone	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	autograft	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	commonly	_	_	RB	_	_	_	_	_
21	harvested	_	_	VBN	_	_	_	_	_
22	from	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	iliac	_	_	NN	_	_	_	_	_
25	crest	_	_	NN	_	_	_	_	_
26	or	_	_	CC	_	_	_	_	_
27	obtained	_	_	VBN	_	_	_	_	_
28	from	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	surgical	_	_	JJ	_	_	_	_	_
31	site	_	_	NN	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	local	_	_	JJ	_	_	_	_	_
34	bone	_	_	NN	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	autologous	_	_	JJ	_	_	_	_	_
3	bone	_	_	NN	_	_	_	_	_
4	possesses	_	_	VBZ	_	_	_	_	_
5	osteogenic	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	osteoinductive	_	_	JJ	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	osteoconductive	_	_	JJ	_	_	_	_	_
10	abilities	_	_	NNS	_	_	_	_	_
11	;	_	_	:	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	success	_	_	NN	_	_	_	_	_
14	rate	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	spinal	_	_	JJ	_	_	_	_	_
17	fusion	_	_	NN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	autograft	_	_	NN	_	_	_	_	_
20	is	_	_	VBZ	_	_	_	_	_
21	high	_	_	JJ	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	up	_	_	IN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	95	_	_	CD	_	_	_	_	_
26	%	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	autograft	_	_	NN	_	_	_	_	_
4	material	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	limited	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	quantity	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	its	_	_	PRP$	_	_	_	_	_
11	quality	_	_	NN	_	_	_	_	_
12	varies	_	_	VBZ	_	_	_	_	_
13	depending	_	_	VBG	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	patient	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	significant	_	_	JJ	_	_	_	_	_
4	morbidity	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	associated	_	_	VBN	_	_	_	_	_
7	with	_	_	IN	_	_	_	_	_
8	bone	_	_	NN	_	_	_	_	_
9	harvesting	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	previously	_	_	RB	_	_	_	_	_
13	described	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Between	_	_	IN	_	_	_	_	_
2	many	_	_	JJ	_	_	_	_	_
3	alternatives	_	_	NNS	_	_	_	_	_
4	proposed	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	achieve	_	_	VB	_	_	_	_	_
7	spinal	_	_	JJ	_	_	_	_	_
8	fusion	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	MSC	_	_	NNP	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	interesting	_	_	JJ	_	_	_	_	_
13	because	_	_	IN	_	_	_	_	_
14	they	_	_	PRP	_	_	_	_	_
15	can	_	_	MD	_	_	_	_	_
16	provide	_	_	VB	_	_	_	_	_
17	osteogenic	_	_	JJ	_	_	_	_	_
18	properties	_	_	NNS	_	_	_	_	_
19	allowing	_	_	VBG	_	_	_	_	_
20	bone	_	_	NN	_	_	_	_	_
21	regeneration	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	recently	_	_	RB	_	_	_	_	_
3	published	_	_	VBD	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	descriptive	_	_	JJ	_	_	_	_	_
6	systematic	_	_	JJ	_	_	_	_	_
7	literature	_	_	NN	_	_	_	_	_
8	review	_	_	NN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	order	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	understand	_	_	VB	_	_	_	_	_
13	if	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	use	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	MSC	_	_	NNP	_	_	_	_	_
18	may	_	_	MD	_	_	_	_	_
19	represent	_	_	VB	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	valid	_	_	JJ	_	_	_	_	_
22	strategy	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	facilitate	_	_	VB	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	accelerate	_	_	VB	_	_	_	_	_
27	bone	_	_	NN	_	_	_	_	_
28	regeneration	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	fusion	_	_	NN	_	_	_	_	_
31	during	_	_	IN	_	_	_	_	_
32	spine	_	_	NN	_	_	_	_	_
33	surgery	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	review	_	_	NN	_	_	_	_	_
4	we	_	_	PRP	_	_	_	_	_
5	selected	_	_	VBD	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	analyzed	_	_	VBD	_	_	_	_	_
8	50	_	_	CD	_	_	_	_	_
9	relevant	_	_	JJ	_	_	_	_	_
10	papers	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	stratified	_	_	VBN	_	_	_	_	_
13	according	_	_	VBG	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	preclinical	_	_	JJ	_	_	_	_	_
16	studies	_	_	NNS	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	clinical	_	_	JJ	_	_	_	_	_
19	trials	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Preclinical	_	_	JJ	_	_	_	_	_
2	published	_	_	VBN	_	_	_	_	_
3	data	_	_	NNS	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	MSC	_	_	NNP	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	potential	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	achieve	_	_	VB	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	facilitate	_	_	VB	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	accelerate	_	_	VB	_	_	_	_	_
16	spinal	_	_	JJ	_	_	_	_	_
17	fusion	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	preclinical	_	_	JJ	_	_	_	_	_
4	studies	_	_	NNS	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	animal	_	_	NN	_	_	_	_	_
7	models	_	_	NNS	_	_	_	_	_
8	indicated	_	_	VBD	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	some	_	_	DT	_	_	_	_	_
11	barriers	_	_	NNS	_	_	_	_	_
12	remain	_	_	VBP	_	_	_	_	_
13	prior	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	this	_	_	DT	_	_	_	_	_
16	therapy	_	_	NN	_	_	_	_	_
17	translation	_	_	NN	_	_	_	_	_
18	into	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	clinical	_	_	JJ	_	_	_	_	_
21	application	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	So	_	_	RB	_	_	_	_	_
2	far	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	few	_	_	JJ	_	_	_	_	_
5	published	_	_	VBN	_	_	_	_	_
6	clinical	_	_	JJ	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	employ	_	_	VBP	_	_	_	_	_
9	stem	_	_	NN	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	spinal	_	_	JJ	_	_	_	_	_
13	fusion	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Most	_	_	JJS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	them	_	_	PRP	_	_	_	_	_
4	used	_	_	VBD	_	_	_	_	_
5	concentrated	_	_	VBN	_	_	_	_	_
6	autologous	_	_	JJ	_	_	_	_	_
7	BM	_	_	NN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	primary	_	_	JJ	_	_	_	_	_
10	source	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	stem	_	_	NN	_	_	_	_	_
13	cells	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	they	_	_	PRP	_	_	_	_	_
16	showed	_	_	VBD	_	_	_	_	_
17	fusion	_	_	NN	_	_	_	_	_
18	results	_	_	NNS	_	_	_	_	_
19	ranging	_	_	VBG	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	87	_	_	CD	_	_	_	_	_
22	%	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	92.3	_	_	CD	_	_	_	_	_
25	%	_	_	NN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	total	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	297	_	_	CD	_	_	_	_	_
31	patients	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_

